Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9006798 | 1.00 | ADRB3 (0.83) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL9317518 | 0.99 | ADRB3 (0.82) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2052478 | 0.92 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL6931932 | 0.92 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL29373533 | 0.92 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9006793 | 0.92 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL5200899 | 0.92 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3898164 | 0.92 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL8765764 | 0.92 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3824162 | 0.92 | ADRB3 (0.91) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966276-B1 | USE OF BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR PREPARING WOUND-HEALING PHARMACEUTICALS | SANOFI SYNTHELABO (FR) | 2003-12-10 | — | — | EP | claimed |
| EP-0403360-B1 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI SA (FR) | 1996-10-16 | — | — | EP | claimed |
| EP-0303546-B1 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI SA (FR) | 1994-12-28 | — | — | EP | claimed |
| EP-0403360-A2 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI (FR) | 1990-12-19 | — | — | EP | claimed |
| US-4927955-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI (FR) | 1990-05-22 | — | — | US | claimed |
| EP-0303546-A2 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI (FR) | 1989-02-15 | — | — | EP | claimed |
| US-20050026986-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | US | disclosed |
| EP-0966276-B1 | USE OF BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR PREPARING WOUND-HEALING PHARMACEUTICALS | SANOFI SYNTHELABO (FR) | 2003-12-10 | — | — | EP | disclosed |
| US-20020128302-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | MARUANI JEANNE (FR) | 2002-09-12 | — | — | US | disclosed |
| US-6344474-B1 | Use of central cannabinoid receptor antagonists for regulating appetence | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | disclosed |
| EP-0969835-A1 | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR REGULATING APPETENCE | SANOFI-SYNTHELABO (FR) | 2000-01-12 | — | — | EP | disclosed |
| EP-0966276-A1 | USE OF AGONISTS OF ADRENERGIC BETA-3 RECEPTORS FOR PREPARING WOUND-HEALING MEDICINES | SANOFI-SYNTHELABO (FR) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998032441-A1 | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR REGULATING APPETENCE | SANOFI-SYNTHELABO (FR) | 1998-07-30 | — | — | WO | disclosed |
| EP-0303546-B1 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI SA (FR) | 1994-12-28 | — | — | EP | disclosed |
| US-5347037-A | (RR) and (RS stereoisomers of N-(7-ethoxycarbonylmethoxy-1,2,3,-tetrahydronaphth-2-yl)-2-(3-chlorophenyl)-2-hydroxyethanamine and their pharmaceutically acceptable salts | SANOFI (FR) | 1994-09-13 | — | — | US | disclosed |
| US-5236951-A | Administering a phenylethanolamine derivative | SANOFI (FR) | 1993-08-17 | — | — | US | disclosed |
| US-5041606-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI | 1991-08-20 | — | — | US | disclosed |
| EP-0403360-A2 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI (FR) | 1990-12-19 | — | — | EP | disclosed |
| US-4927955-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI (FR) | 1990-05-22 | — | — | US | disclosed |
| EP-0303546-A2 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026986-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | CNR1, CNR2, ADRB3 | ADRB3 3/4885ADRB1 4/4885 |
| US-20020128302-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | CNR1, CNR2, GPR119 | ADRB3 4/4885ADRB1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.